NEW YORK, Nov. 16, 2015 /PRNewswire/ -- Summary
Clostridium difficile infections (CDI) are primarily transmitted through the fecal-oral route. There are two major sources of CDI: healthcare-associated CDI (HA-CDI) and community-associated CDI (CA-CDI). The typical clinical symptoms of CDI range from watery diarrhea, anorexia, and nausea, to hypoalbuminemia and abdominal tenderness in severe cases. Though suspected in all patients with antibiotic-associated diarrhea, the confirmatory diagnosis of CDI is primarily based on the combination of clinical features exhibited by the patient and the results of various laboratory tests including stool tests, as well as, in certain rare scenarios, endoscopy or radiologic tests. Recurrence and complications of CDI usually pose grave challenges for the treatment and management of this condition and occur in about 20-30% of the patients treated successfully for their first episode.
GlobalData epidemiologists predict that the diagnosed incident cases of all-CDI will grow from 686,540 cases in 2014 to 825,021 cases in 2024, at an Annual Growth Rate (AGR) of 2.02% over the 10-year forecast period. Throughout the forecast period, the US will have the highest number of diagnosed incident cases of all-CDI in the 7MM.
This report provides an overview of the risk factors, comorbidities, and the global and historical trends for CDI in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all-CDI segmented by sex and by age (in five-year age groups beginning at 18 years and ending at =85 years). The term all-CDI is defined as any instance of suspected CDI and diarrhea, with stool samples testing positive for toxin A, B, or both (enzyme immunoassay [EIA], cytotoxicity test, or polymerase chain reaction [PCR]) or revealing the presence of toxin-producing C. difficile, and includes both HA-CDI and CA-CDI. The report also provides the 10-year epidemiology forecast for the all-CDI cases segmented by epidemiological association into HA-CDI and CA-CDI. Additionally, the report provides a 10-year epidemiological forecast for the recurrent all-CDI cases with a further segmentation by number of recurrences.
- The Clostridium difficile infection (CDI) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for CDI in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all-CDI segmented by sex and by age (in five-year age groups beginning at 18 years and ending at =85 years).
- The CDI epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Clostridium Difficile Infection (CDI) EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CDI market.
- Quantify patient populations in the global CDI market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CDI therapeutics in each of the markets covered.
Read the full report: http://www.reportlinker.com/p03389021-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001